Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Research & Development: 2021-2022

Historic Research & Development for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to $3.9 million.

  • Cardiol Therapeutics' Research & Development rose 89.51% to $3.9 million in Q3 2022 from the same period last year, while for Sep 2022 it was $13.2 million, marking a year-over-year change of. This contributed to the annual value of $8.7 million for FY2021, which is 9.59% up from last year.
  • Per Cardiol Therapeutics' latest filing, its Research & Development stood at $3.9 million for Q3 2022, which was up 12.89% from $3.5 million recorded in Q2 2022.
  • Over the past 5 years, Cardiol Therapeutics' Research & Development peaked at $3.9 million during Q3 2022, and registered a low of $1.7 million during Q2 2021.
  • Its 2-year average for Research & Development is $2.7 million, with a median of $2.8 million in 2021.
  • Data for Cardiol Therapeutics' Research & Development shows a peak YoY soared of 105.10% (in 2022) over the last 5 years.
  • Cardiol Therapeutics' Research & Development (Quarterly) stood at $2.8 million in 2021, then surged by 89.51% to $3.9 million in 2022.
  • Its Research & Development was $3.9 million in Q3 2022, compared to $3.5 million in Q2 2022 and $3.0 million in Q1 2022.